These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24279793)

  • 1. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells.
    Zhang M; Truscott J; Davie J
    Mol Cancer; 2013 Nov; 12(1):150. PubMed ID: 24279793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.
    Zhang M; Zhu B; Davie J
    J Biol Chem; 2015 Jan; 290(1):310-24. PubMed ID: 25404735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
    Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
    Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
    Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
    Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.
    Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C
    Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.
    Tonin PN; Scrable H; Shimada H; Cavenee WK
    Cancer Res; 1991 Oct; 51(19):5100-6. PubMed ID: 1717137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma.
    Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z
    J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEF2D Functions as a Tumor Suppressor in Breast Cancer.
    Wang X; Shen H; Chen Y; Zhang Y; Wang J; Liu S; Xu B; Wang H; Frangou C; Zhang J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel small molecule DMAMCL induces differentiation in rhabdomyosarcoma by downregulating of DLL1.
    Li Q; Chen Y; Chen Y; Hua Z; Gong B; Liu Z; Thiele CJ; Li Z
    Biomed Pharmacother; 2024 May; 174():116562. PubMed ID: 38626518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase.
    Kucharczak J; Charrasse S; Comunale F; Zappulla J; Robert B; Teulon-Navarro I; Pèlegrin A; Gauthier-Rouvière C
    Cancer Res; 2008 Aug; 68(16):6559-68. PubMed ID: 18701479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.
    Huang HJ; Liu J; Hua H; Li SE; Zhao J; Yue S; Yu TT; Jin YC; Cheng SY
    Oncotarget; 2014 Apr; 5(8):2161-75. PubMed ID: 24811402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.
    Faggi F; Chiarelli N; Colombi M; Mitola S; Ronca R; Madaro L; Bouche M; Poliani PL; Vezzoli M; Longhena F; Monti E; Salani B; Maggi D; Keller C; Fanzani A
    Lab Invest; 2015 Jun; 95(6):585-602. PubMed ID: 25822667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding.
    Li S; Chen K; Zhang Y; Barnes SD; Jaichander P; Zheng Y; Hassan M; Malladi VS; Skapek SX; Xu L; Bassel-Duby R; Olson EN; Liu N
    Genes Dev; 2019 Jun; 33(11-12):626-640. PubMed ID: 30975722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.